The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Issue 1 (4th July 2017)

• Record Type: Journal Article
• Authors: Bahrami, Afsane; Khazaei, Majid; Shahidsales, Soodabeh; Hassanian, Seyed Mahdi; Hasanzadeh, Malihe; Maftouh, Mina; Ferns, Gordon A.; Avan, Amir
• Is Part Of: Journal of cellular biochemistry. Volume 119:Issue 1(2018)
• Page Start: 213
• Page End: 222
• Publication Date: 2017-07-04
• Subjects: PI3K/Akt/mTOR INHIBITORS -- EVEROLIMUS -- BREAST CANCER; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.26136
• Languages: English
• ISSNs: 0730-2312

Abstract

ABSTRACT: Breast cancer (BC) is the most commonly diagnosed cancer in women. The PI3K/AKT/mTOR pathway is among the most frequently dysregulated pathways in patients with BC. The activation of this pathway is associated with increased cell growth and clinical outcome, and its overexpression is associated with a poor prognosis. It has been proposed that it may be of importance as a potential therapeutic target in the treatment of BC. The aim of current review is to provide an overview of the potential utility of PI3K/Akt/mTOR inhibitors in patients with BC, with particular emphasis on recent preclinical and clinical studies. J. Cell. Biochem. 119: 213–222, 2018. © 2017 Wiley Periodicals, Inc.